Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies

• Lucía Campos-Prieto,
• Aitor García-Rey,
• Eddy Sotelo and
• Ana Mallo-Abreu

Beilstein J. Org. Chem. 2024, 20, 3151–3173, doi:10.3762/bjoc.20.261

• deacetylase substrate MAL to determine the inhibitory activity, and using sirtinol as positive control. When compared to sirtinol (IC50 = 67 µM), selected compounds showed moderate affinity towards SIRT2, with IC50 values ranging from 118 to 126 µM (Figure 10). Gewald reaction: Cannabinoid receptors have been

• heterocyclic core. The novel compounds were first evaluated using β-arrestin recruitment assays in CHO (chinese hamster ovary) cells overexpressing human GPR55. These new compounds have been evaluated in competitive binding assays for cannabinoid receptors, but all of them showed to be selective for GPR55 (>4

• μM for cannabinoid receptors). Then, the most promising antagonist (14a; IC50 = 0.28 µM) was selected for a G-protein-dependent functional assay, where 14a acted as a weak GPR55 inverse agonist (EC50 = 0.9 µM). Depression and anxiety Benzodiazepines are widely used in treating a range of CNS

Iodine-catalyzed electrophilic substitution of indoles: Synthesis of (un)symmetrical diindolylmethanes with a quaternary carbon center

• Thanigaimalai Pillaiyar,
• Masoud Sedaghati,
• Andhika B. Mahardhika,
• Lukas L. Wendt and
• Christa E. Müller

Beilstein J. Org. Chem. 2021, 17, 1464–1475, doi:10.3762/bjoc.17.102

• , and scalability to obtain gram amounts for biological studies. Selected compounds were found to display affinity for cannabinoid receptors, which are promising drug targets for the treatment of inflammatory and neurodegenerative diseases. Keywords: alkylation of indole; anti-inflammatory; binding

• affinity; cannabinoid receptors; diindolylmethane; unsymmetrical 3,3'-diindolylmethane; Introduction Diindolylmethanes (DIMs) represent an important class of indole alkaloids, that are constituents of pharmaceuticals [1][2][3][4][5][6][7] and agrochemicals [8][9]. DIM derivatives possess a variety of

• previously reported to bind to the cannabinoid receptors, CB1 (Ki 4.3 µM) and CB2 (Ki 1.1 µM) [41]. Both receptors are considered important therapeutic targets, e.g. for neurodegenerative and inflammatory diseases. Selected final products (3a, 3b, 3e, 3g, 3h, 3n, 3ad) were tested for their binding affinities